Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914511 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects
A Phase 1 study of Avanfil ADME and Semen Exposure, sponsored by VIVUS.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00914511 is a Phase 1 study of Avanfil ADME and Semen Exposure that has completed, run by VIVUS. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00914511, a Phase 1 study of Avanfil ADME and Semen Exposure, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to: * Determine the effect of the study drug on sperm and semen of healthy young male subjects. * Determine the effect of age on the amount of study drug in the blood of healthy subjects * Learn about the safety of the study drug. * Learn how subjects tolerate the study drug.
Conditions Studied
Interventions
- DRUG avanafil 200mg
Study Locations (1)
Arizona
- MDS Pharma Services - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914511
The ClinicalTrials.gov registry entry for NCT00914511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Avanfil ADME appearing as the primary indexed condition, and to 1 intervention - of which avanafil 200mg is the first listed.
NCT00914511 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT00914511 about?
NCT00914511 is a clinical study titled "A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects". The purposes of this study are to: * Determine the effect of the study drug on sperm and semen of healthy young male subjects. * Determine the effect of age on the amount of study drug in the blood of healthy subjects * Learn about the safety of the study drug. * Learn how subjects tolerate the stu...
What is the current status of trial NCT00914511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2009-05. Estimated completion is 2009-06.
What conditions does trial NCT00914511 study?
This clinical trial studies the following conditions: Avanfil ADME, Semen Exposure, Sperm Function.
What interventions are being tested in trial NCT00914511?
The interventions under investigation include: avanafil 200mg (DRUG).
Who is sponsoring clinical trial NCT00914511?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00914511 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.